866-997-4948(US-Canada Toll Free)

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Jul 2013

Category :

Cancer

No. of Pages : 234 Pages


Global Markets Directs, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. 

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
  • A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer 12
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics under Development by Companies 14
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Pre-Clinical Stage Products 21
Comparative Analysis 21
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Products under Development by Companies 22
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Products under Investigation by Universities/Institutes 24
Companies Involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Development 25
Bristol-Myers Squibb Company 25
Johnson & Johnson 26
AstraZeneca PLC 27
Eli Lilly and Company 28
Genentech, Inc. 29
Bavarian Nordic A/S 30
Merck & Co., Inc. 31
Emergent BioSolutions Inc. 32
Takeda Pharmaceutical Company Limited 33
Millennium Pharmaceuticals, Inc. 34
Novartis AG 35
GTx, Inc. 36
Teva Pharmaceutical Industries Limited 37
Progenics Pharmaceuticals, Inc. 38
Exelixis, Inc. 39
Aduro BioTech 40
Merck KGaA 41
Active Biotech AB 42
Oncolytics Biotech Inc. 43
Oncothyreon Inc 44
Osta Biotechnologies Inc. 45
Medivation, Inc. 46
Synta Pharmaceuticals Corp. 47
Supratek Pharma Inc. 48
CellCentric Ltd. 49
CureVac GmbH 50
GenSpera, Inc. 51
BIND Biosciences, Inc. 52
NewLink Genetics Corporation 53
Bellicum Pharmaceuticals, Inc. 54
TRACON Pharmaceuticals, Inc. 55
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
ipilimumab - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
pasireotide - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
patupilone - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DI-17-E-6 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
orteronel - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
cixutumumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
vandetanib - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
PSMA ADC - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
GTx-758 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
custirsen sodium - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
ridaforolimus - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
tasquinimod - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
enzalutamide - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
panobinostat - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
dasatinib - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
cabozantinib - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
ganetespib - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
rilimogene galvacirepvec - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
pelareorep - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
PX-866 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
carlumab - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
G-202 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
BMTP-11 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
docetaxel targeted nanoparticles - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
atrasentan hydrochloride - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
buparlisib - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
NLG-8189 - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
CreaVax-PC - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
GVAX Prostate Cancer Vaccine - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
TL-118 - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
OB-24 - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 138
RG-7450 - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
ES-414 - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
CV-9104 - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 142
Dendritic Cell Vaccine + [docetaxel] - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 143
Deubiquitinase Program - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
cabazitaxel nanoformulation - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
Compound-54 - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
DCVAC/PCa - Drug Profile 147
Product Description 147
Mechanism of Action 147
R&D Progress 147
ATL-101 - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
AbIMP Targeting ADAM15 - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Drug Profile Updates 152
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Discontinued Products 220
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Dormant Products 221
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Product Development Milestones 223
Featured News & Press Releases 223
Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway 223
Jun 05, 2013: Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America 224
Jun 02, 2013: Seattle Genetics Announces Presentation Of Genentechs RG-7450 Phase I Study At ASCO Annual Meeting 2013 224
Jun 01, 2013: Progenics Pharma Presents Findings From Phase I Study Of PSMA ADC At ASCO 2013 Annual Meeting 225
May 27, 2013: Bavarian Nordic Announces Presentation Of Prostvac At 2013 ASCO Annual Meeting 226
May 24, 2013: Astellas And Medivation Announce Submission Of Application For Marketing Approval Of Enzalutamide In Japan 226
Apr 26, 2013: Astellas Pharma And Medivation Announce CHMP Positive Opinion For Xtandi For Treatment Of Metastatic Castration-resistant Prostate Cancer 227
Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium 228
Feb 14, 2013: Progenics Pharma Presents Updated Data From Phase I Study Of PSMA ADC At 2013 Genitourinary Cancers Symposium 229
Feb 13, 2013: Medivation And Astellas Pharma Announce Presentation Of Data On Enzalutamide At ASCO GU Symposium 230

Appendix 233
Methodology 233
Coverage 233
Secondary Research 233
Primary Research 233
Expert Panel Validation 233
Contact Us 234
Disclaimer 234

List of Table


Number of Products Under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2013 12
Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Comparative Analysis, H2 2013 13
Number of Products under Development by Companies, H2 2013 15
Number of Products under Development by Companies, H2 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2013 17
Comparative Analysis by Late Stage Development, H2 2013 18
Comparative Analysis by Mid Clinical Stage Development, H2 2013 19
Comparative Analysis by Early Clinical Stage Development, H2 2013 20
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 21
Products under Development by Companies, H2 2013 22
Products under Development by Companies, H2 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2013 24
Bristol-Myers Squibb Company, H2 2013 25
Johnson & Johnson, H2 2013 26
AstraZeneca PLC, H2 2013 27
Eli Lilly and Company, H2 2013 28
Genentech, Inc., H2 2013 29
Bavarian Nordic A/S, H2 2013 30
Merck & Co., Inc., H2 2013 31
Emergent BioSolutions Inc., H2 2013 32
Takeda Pharmaceutical Company Limited, H2 2013 33
Millennium Pharmaceuticals, Inc., H2 2013 34
Novartis AG, H2 2013 35
GTx, Inc., H2 2013 36
Teva Pharmaceutical Industries Limited, H2 2013 37
Progenics Pharmaceuticals, Inc., H2 2013 38
Exelixis, Inc., H2 2013 39
Aduro BioTech, H2 2013 40
Merck KGaA, H2 2013 41
Active Biotech AB, H2 2013 42
Oncolytics Biotech Inc., H2 2013 43
Oncothyreon Inc, H2 2013 44
Osta Biotechnologies Inc., H2 2013 45
Medivation, Inc., H2 2013 46
Synta Pharmaceuticals Corp., H2 2013 47
Supratek Pharma Inc., H2 2013 48
CellCentric Ltd., H2 2013 49
CureVac GmbH, H2 2013 50
GenSpera, Inc., H2 2013 51
BIND Biosciences, Inc., H2 2013 52
NewLink Genetics Corporation, H2 2013 53
Assessment by Monotherapy Products, H2 2013 56
Assessment by Combination Products, H2 2013 57
Assessment by Stage and Route of Administration, H2 2013 59
Assessment by Stage and Molecule Type, H2 2013 61
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Drug Profile Updates 152
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Discontinued Products 220
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products 221
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Dormant Products (Contd..1) 222

List of Chart


Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2013 12
Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Comparative Analysis, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 17
Late Stage Products, H2 2013 18
Mid Clinical Stage Products, H2 2013 19
Early Clinical Stage Products, H2 2013 20
Pre-Clinical Stage Products, H2 2013 21
Assessment by Monotherapy Products, H2 2013 56
Assessment by Combination Products, H2 2013 57
Assessment by Route of Administration, H2 2013 58
Assessment by Stage and Route of Administration, H2 2013 59
Assessment by Molecule Type, H2 2013 60
Assessment by Stage and Molecule Type, H2 2013 61

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *